SF
AXSM icon

Synovus Financial’s Axsome Therapeutics AXSM Stock Holding History

Synovus Financial’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.69M Sell
22,156
-170
-0.8% -$19.1K 0.03% 302
2025
Q2 		$2.33M Buy
22,326
+773
+4% +$81.9K 0.03% 327
2025
Q1 		$2.51M Buy
21,553
+5,425
+34% +$618K 0.03% 306
2024
Q4 		$1.36M Buy
16,128
+278
+2% +$25.6K 0.02% 412
2024
Q3 		$1.42M Buy
15,850
+18
+0.1% +$1.57K 0.02% 436
2024
Q2 		$1.27M Buy
15,832
+178
+1% +$13.2K 0.02% 410
2024
Q1 		$1.25M Buy
+15,654
New +$1.31M 0.02% 409

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Synovus Financial's AXSM Position: Q3 2025 in Review

Synovus Financial reduced its Axsome Therapeutics (AXSM) stake by 0.76% in Q3 2025, selling an estimated $19.1K and leaving 22,156 shares worth $2.69M. The position accounts for 0.03% of the portfolio, ranked #302.

Synovus Financial first reported a position in AXSM in Q1 2024 and has held it in 7 quarters since. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Synovus Financial held 22,156 shares of Axsome Therapeutics worth $2.69M as of Q3 2025.
  • Synovus Financial sold 170 Axsome Therapeutics shares in Q3 2025, an estimated $19.1K.
  • Axsome Therapeutics made up 0.03% of Synovus Financial's portfolio in Q3 2025, its #302 holding.
  • Synovus Financial first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Synovus Financial's 13F filing for Q3 2025, filed 7 Nov 2025.